GASTROESOPHAGEAL JUNCTION CANCER

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This study is for people with HER2-positive esophageal or gastroesophageal junction cancer who have already completed chemoradiation and surgery. The goal is to see if adding a year of treatment with trastuzumab deruxtecan (Enhertu) plus nivolumab is safe and helps prevent the ca…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before standard chemoradiation is safe and feasible for people with operable stage II/III esophageal or gastroesophageal junction cancer. About 32 adults will receive the drugs, then chemorad…

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This study tests whether giving immunotherapy before surgery can help people with MSI/dMMR tumors. The goal is to shrink or eliminate the tumor before it is removed, potentially improving survival. The trial includes adults with localized, resectable cancers such as colorectal, g…

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a new drug called bemarituzumab, given together with chemotherapy and an immunotherapy drug (nivolumab), in 72 adults with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The main goals are to check safety and see if the co…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This study explores whether a special PET/MRI scan can predict how well esophageal cancer responds to chemotherapy and radiation given before surgery. Researchers will scan 121 patients during treatment and compare the images with the actual tumor response seen after surgery. The…